Regorafenib VEGFR Inhibitors

Regorafenib, also known as BAY 73-4506 ; is an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. Regorafenib demonstrated to increase the overall survival of patients with metastatic colorectal cancer and has been approved by the US FDA on September 27, 2012.

Related Prodcuts:

Sorafenib; Cabozantinib; Cabozantinib malate; Ponatinib; Axitinib; Vandetanib; Nintedanib; Pazopanib HCl; Pazopanib; Cediranib; Dovitinib; Lenvatinib; Tivozanib; Sorafenib Tosylate; Sunitinib Malate

• [1] Wilhelm SM, et al. Int J Cancer, 2011, 129(1), 245-255.
• [2] Heng DY, et al. Ther Adv Med Oncol, 2010, 2(1), 39-49.
• [3] Carr BI, et al. J Cell Physiol, 2013, 228(2), 292-297.